Garelick, Daniela;
Isenberg, David A;
(2025)
Baby you can drive my CAR-T cells.
Lupus
, 34
(7)
pp. 653-656.
10.1177/09612033251335798.
Preview |
Text
Isenberg_garelick-isenberg-2025-baby-you-can-drive-my-car-t-cells.pdf Download (504kB) | Preview |
Abstract
Objective: To evaluate the potential of chimeric antigen receptor T-cell (CAR-T) therapy in revolutionizing the treatment of systemic lupus erythematosus (SLE) and to outline necessary future steps for its implementation. Methods: A careful literature search was conducted for relevant English language papers on pubmed. Results: Preliminary data suggest that CAR-T therapy could significantly improve SLE outcomes. Demonstrating remarkable clinical and serologic improvements in SLE patients, with all treated patients achieving remission and discontinuing conventional steroids and immunosuppressive drugs. To realize this potential, it is imperative to advance our understanding and application of CAR-T therapy. Rigorous research is necessary to validate current findings, and clinical trials must be conducted to assess both the short- and long-term efficacy and safety across diverse populations. Identifying appropriate patient populations is crucial, as CAR-T may also address compliance issues. Despite its current high cost, the financial burden is comparable to the long-term costs of severe SLE treatment. Strategies to reduce costs, including production efficiencies and outpatient treatment options, are under exploration. Early intervention could enhance its feasibility and impact on long-term prognosis. Conclusion: CAR-T therapy holds promise for altering the prognosis of SLE and potentially offering a cure. However, substantial efforts are required to validate its efficacy, ensure safety, identify suitable patient cohorts, and reduce financial barriers. This development represents an exciting advancement in SLE treatment, necessitating urgent and focused research and clinical application.
| Type: | Article |
|---|---|
| Title: | Baby you can drive my CAR-T cells |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1177/09612033251335798 |
| Publisher version: | https://doi.org/10.1177/09612033251335798 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons License. The images or other third-party material in this article are included in the Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit https://creativecommons.org/licenses/by-nc/4.0/deed.en |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Rheumatology, Renal lupus, systemic lupus erythematosus, anti-DNA antibodies, SYSTEMIC-LUPUS-ERYTHEMATOSUS, THERAPY, OUTCOMES |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10215561 |
Archive Staff Only
 |
View Item |
